|
Neurodegenerative Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Biochemical and genetic evidence point towards alpha-synuclein aggregation as having a pivotal role in the onset and progression of several neurodegenerative disorders, including Parkinson's disease, multiple system atrophy and Lewy body dementia.
|
15790525 |
2005 |
|
Neurodegenerative Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
There is strong evidence for the involvement of alpha-synuclein in the pathologies of several neurodegenerative disorders, including PD (Parkinson's disease).
|
16246056 |
2005 |
|
Neurodegenerative Disorders
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Pathological brain inclusions comprised of alpha-synuclein or tau proteins are associated with a spectrum of neurodegenerative disorders, and oxidative and nitrative injury has been implicated in all of these diseases.
|
15890012 |
2005 |
|
Neurodegenerative Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Filamentous alpha-synuclein depositions are the defining hallmarks of a subset of neurodegenerative diseases including Parkinson's disease (PD), dementia with Lewy bodies, and multiple system atrophy.
|
15628878 |
2005 |
|
Neurodegenerative Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Fibrillization and aggregation of alpha-synuclein may play a critical role in neurodegenerative diseases like Parkinson's diseases.
|
16460685 |
2006 |
|
Neurodegenerative Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Further, we demonstrate that archaeal proteasome can also degrade other neurodegenerative disease-associated proteins such as alpha-synuclein and tau.
|
16793767 |
2006 |
|
Neurodegenerative Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Mutations in alpha-synuclein gene cause familial form of Parkinson disease, and deposition of wild-type alpha-synuclein as Lewy bodies occurs as a hallmark lesion of sporadic Parkinson disease and dementia with Lewy bodies, implicating alpha-synuclein in the pathogenesis of Parkinson disease and related neurodegenerative diseases.
|
16260788 |
2006 |
|
Neurodegenerative Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Parkinson's disease (PD) is a neurodegenerative disorder characterized by fibrillar aggregates of alpha-synuclein in characteristic inclusions known as "Lewy bodies".
|
16959793 |
2006 |
|
Neurodegenerative Disorders
|
0.400 |
GeneticVariation
|
group |
LHGDN |
Synphilin-1A: an aggregation-prone isoform of synphilin-1 that causes neuronal death and is present in aggregates from alpha-synucleinopathy patients.
|
16595633 |
2006 |
|
Neurodegenerative Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Alpha-synuclein (alphaSyn) misfolding is associated with several devastating neurodegenerative disorders, including Parkinson's disease (PD).
|
16794039 |
2006 |
|
Neurodegenerative Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Aberrant aggregation of alpha-synuclein (alpha-syn) to form fibrils and insoluble aggregates has been implicated in the pathogenic processes of many neurodegenerative diseases.
|
17005870 |
2006 |
|
Neurodegenerative Disorders
|
0.400 |
Biomarker
|
group |
LHGDN |
These findings revealed a new, possibly regulatory, modification of tau and alpha-synuclein that may also have implications for their pathogenic roles in neurodegenerative diseases.
|
16464864 |
2006 |
|
Neurodegenerative Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Thus, the deposition of alpha-synuclein, an abundant presynaptic brain protein, as fibrillary aggregates in affected neurons or glial cells, was highlighted as a hallmark lesion of a subset of neurodegenerative disorders, including PD, DLB and multiple system atrophy collectively referred to as synucleinopathies.
|
18018483 |
2007 |
|
Neurodegenerative Disorders
|
0.400 |
GeneticVariation
|
group |
BEFREE |
The adverse effects of aging on neuronal Ca2+ regulation are subject to modification by genetic (mutations in presenilins, alpha-synuclein, huntingtin, or Cu/Zn-superoxide dismutase; apolipoprotein E isotype, etc.) and environmental (dietary energy intake, exercise, exposure to toxins, etc.) factors that may cause or affect the risk of neurodegenerative disease.
|
17328689 |
2007 |
|
Neurodegenerative Disorders
|
0.400 |
Biomarker
|
group |
CTD_human |
Adult-onset neurodegeneration with brain iron accumulation and cortical alpha-synuclein and tau pathology: a distinct clinicopathological entity.
|
17296847 |
2007 |
|
Neurodegenerative Disorders
|
0.400 |
PosttranslationalModification
|
group |
BEFREE |
Recent studies have shown the co-existence of alpha-synuclein and phosphorylated tau (pTau) in several neurodegenerative diseases.
|
17237936 |
2007 |
|
Neurodegenerative Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
alpha-Synuclein is a primarily neuronal protein that is enriched at the pre-synapse. alpha-Synuclein and the microtubule binding protein tau have been implicated in neurodegenerative diseases. alpha-Synuclein is known to associate with phospholipid vesicles, regulates dopamine metabolism and exhibits chaperone activity, but its main role remains largely unknown.
|
17408955 |
2007 |
|
Neurodegenerative Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Alpha-synuclein is involved in dopaminergic neurotransmission and has been implicated in a number of neurodegenerative disorders, such as Parkinson's disease.
|
17374033 |
2007 |
|
Neurodegenerative Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Aggregation of alpha-synuclein, an abundant and conserved pre-synaptic brain protein, is implicated as a critical factor in several neurodegenerative diseases.
|
17623039 |
2007 |
|
Neurodegenerative Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Alpha-synuclein has been implicated in the pathology of certain neurodegenerative diseases, including Parkinson disease (PD) and dementia with Lewy bodies (LBs).
|
17337120 |
2007 |
|
Neurodegenerative Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Although alpha-synuclein has been implicated in several neurodegenerative disorders including Parkinson's disease, dementia with Lewy bodies and multiple system atrophy, its functions remain largely unclear.
|
17653558 |
2007 |
|
Neurodegenerative Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Aggregation of alpha-synuclein (alpha-syn) has been linked to the pathogenesis of Parkinson's disease (PD) and other neurodegenerative diseases.
|
17715357 |
2007 |
|
Neurodegenerative Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
These findings have potentially important implications for understanding the interface between tau and alpha-synuclein pathways in neurodegenerative disorders and for unraveling the biological basis for cognitive impairment and dementia in PD.
|
17683088 |
2007 |
|
Neurodegenerative Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Moreover, alpha-synuclein- and ubiquitin-positive inclusion bodies are the pathological hallmarks of PD and several other neurodegenerative diseases, such as dementia with Lewy bodies and multiple system atrophy.
|
18065497 |
2008 |
|
Neurodegenerative Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized pathologically by the degeneration of nigrostriatal pathway dopaminergic neurons and other neuronal systems and the appearance of Lewy bodies that contain alpha-synuclein.
|
18590612 |
2008 |